Hypermarcas (OTCMKTS:HYPMY) Sees Strong Trading Volume - Here's What Happened

Key Points

• Unusually strong trading volume: Approximately 82,345 HYPMY shares traded Wednesday — a 315% increase from the prior session — while the stock last traded at $4.35 (previous close $4.35).
• Solid recent results and key metrics: Last quarter EPS was $0.13 on $414.22M revenue with a 15.71% net margin and 10.27% ROE; the company has a market cap of $2.76 billion, a P/E of 12.79, debt-to-equity of 0.61 and a current ratio of 1.27.

Shares of Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 82,345 shares changed hands during trading, an increase of 315% from the previous session's volume of 19,834 shares.The stock last traded at $4.35 and had previously closed at $4.35.

Hypermarcas Price Performance

The company has a debt-to-equity ratio of 0.61, a current ratio of 1.27 and a quick ratio of 0.84. The stock's fifty day simple moving average is $4.44 and its 200-day simple moving average is $4.42. The stock has a market cap of $2.76 billion, a P/E ratio of 12.79 and a beta of 0.73.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported $0.13 EPS for the quarter. The company had revenue of $414.22 million during the quarter. Hypermarcas had a return on equity of 10.27% and a net margin of 15.71%.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.